KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Investing Activities: 2017-2025

Historic Cash from Investing Activities for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to -$235,000.

  • Aquestive Therapeutics' Cash from Investing Activities fell 193.75% to -$235,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$492,000, marking a year-over-year decrease of 207.50%. This contributed to the annual value of -$159,000 for FY2024, which is 84.02% up from last year.
  • As of Q3 2025, Aquestive Therapeutics' Cash from Investing Activities stood at -$235,000, which was down 119.63% from -$107,000 recorded in Q2 2025.
  • Over the past 5 years, Aquestive Therapeutics' Cash from Investing Activities peaked at -$2,000 during Q1 2023, and registered a low of -$1.7 million during Q3 2022.
  • Over the past 3 years, Aquestive Therapeutics' median Cash from Investing Activities value was -$80,000 (recorded in 2024), while the average stood at -$148,273.
  • Per our database at Business Quant, Aquestive Therapeutics' Cash from Investing Activities plummeted by 1,968.67% in 2022 and then soared by 98.08% in 2023.
  • Aquestive Therapeutics' Cash from Investing Activities (Quarterly) stood at -$533,000 in 2021, then soared by 95.12% to -$26,000 in 2022, then surged by 38.46% to -$16,000 in 2023, then increased by 6.25% to -$15,000 in 2024, then tumbled by 193.75% to -$235,000 in 2025.
  • Its last three reported values are -$235,000 in Q3 2025, -$107,000 for Q2 2025, and -$135,000 during Q1 2025.